Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00102817 · ClinicalTrials.gov registry record · Phase 3
Somatropin (Norditropin) in Insulin-like Growth Factor (IGF) Deficient Children
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 149
- Enrollment target
NCT00102817 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 149 participants.
The verdict
NCT00102817, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 149 participants
- Enrollment target
Study Summary
This trial is conducted in the United States of America (USA). This is a 12 month study to determine if Norditropin is safe and effective in children with IGF deficiency.
Interventions
- DRUG somatropin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 149 participants |
| Start Date | 2003-05 |
| Est. Completion | 2006-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00102817
The ClinicalTrials.gov registry entry for NCT00102817 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 149 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which somatropin is the first listed.
NCT00102817 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00102817 about?
NCT00102817 is a clinical study titled "Somatropin (Norditropin) in Insulin-like Growth Factor (IGF) Deficient Children". This trial is conducted in the United States of America (USA). This is a 12 month study to determine if Norditropin is safe and effective in children with IGF deficiency.
What is the current status of trial NCT00102817?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 149 participants. The study started on 2003-05. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00102817?
The interventions under investigation include: somatropin (DRUG).
Who is sponsoring clinical trial NCT00102817?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.